Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Minerva Neuroscie (NERV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 476,871
  • Shares Outstanding, K 38,770
  • Annual Sales, $ 0 K
  • Annual Income, $ -31,520 K
  • 36-Month Beta 1.61
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.37
  • Number of Estimates 1
  • High Estimate -0.37
  • Low Estimate -0.37
  • Prior Year -0.28
  • Growth Rate Est. (year over year) -32.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.35 +33.69%
on 09/11/18
12.85 -2.72%
on 09/25/18
+2.40 (+23.76%)
since 08/24/18
3-Month
7.15 +74.83%
on 08/07/18
12.85 -2.72%
on 09/25/18
+3.95 (+46.20%)
since 06/25/18
52-Week
4.80 +160.42%
on 11/14/17
12.85 -2.72%
on 09/25/18
+5.55 (+79.86%)
since 09/25/17

Most Recent Stories

More News
J&J Submits NDA to the FDA for Depression Drug in Adults

Johnson & Johnson (JNJ) submits NDA to the FDA for esketamine nasal spray seeking approval for treatment-resistant depression in adults in the United States.

JNJ : 138.64 (-1.30%)
LLY : 105.70 (+0.10%)
BMY : 61.82 (+0.37%)
NERV : 12.50 (+1.63%)
Minerva Neurosciences Announces Findings Showing Effect of Roluperidone on Brain-Derived Neurotrophic Factor (BDNF)

Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced findings from...

NERV : 12.50 (+1.63%)
New Research Coverage Highlights EMCORE, Earthstone Energy, Pareteum, Lydall, Minerva Neurosciences, and Drive Shack -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of EMCORE Corporation (NASDAQ:EMKR),...

LDL : 41.70 (-3.14%)
TEUM : 2.98 (+0.34%)
EMKR : 4.50 (-1.10%)
ESTE : 9.62 (-0.82%)
NERV : 12.50 (+1.63%)
DS : 5.87 (-0.17%)
Minerva Neurosciences: 2Q Earnings Snapshot

WALTHAM, Mass. (AP) _ Minerva Neurosciences Inc. (NERV) on Thursday reported a loss of $12.5 million in its second quarter.

NERV : 12.50 (+1.63%)
Minerva Neurosciences Reports Second Quarter 2018 Financial Results and Business Updates

Five ongoing late-stage trials on track for data readouts in 2019

NERV : 12.50 (+1.63%)
Novocure Announces Addition to Its Board of Directors

Novocure (NASDAQ: NVCR) has announced an addition to its board of directors. Jeryl (Jeri) Hilleman, an experienced executive leader, was elected to Novocure's board in July 2018.

NVCR : 50.70 (+3.89%)
XENT : 29.05 (-0.68%)
NERV : 12.50 (+1.63%)
Minerva Neurosciences to Report Second Quarter 2018 Financial Results and Business Updates on August 2, 2018

Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will...

NERV : 12.50 (+1.63%)
Minerva Neurosciences Names Devin Smith Senior Vice President, General Counsel

WALTHAM, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous...

MKKGY : 20.6600 (+0.90%)
NERV : 12.50 (+1.63%)
Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors

Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the election...

XENT : 29.05 (-0.68%)
NERV : 12.50 (+1.63%)
Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symp...

WALTHAM, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system...

NERV : 12.50 (+1.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade NERV with:

Business Summary

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The Company's pipeline will initially target the treatment of schizophrenia, major depressive...

See More

Key Turning Points

2nd Resistance Point 12.77
1st Resistance Point 12.53
Last Price 12.50
1st Support Level 12.03
2nd Support Level 11.77

See More

52-Week High 12.85
Last Price 12.50
Fibonacci 61.8% 9.77
Fibonacci 50% 8.83
Fibonacci 38.2% 7.88
52-Week Low 4.80

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar